Legend Biotech (LEGN) Non-cash Items (2020 - 2025)
Legend Biotech's (LEGN) quarterly Non-cash Items came in at -$20.8 million in Q3 2025, up 57.67% YoY from -$13.2 million in Q3 2024, and down 690.91% on a QoQ basis from $3.5 million in Q2 2025.
Legend Biotech (LEGN) Non-cash Items (2020 - 2025) Analysis & Trends
Legend Biotech (LEGN) has 6 years of Non-cash Items data on file, last reported at -$20.8 million in Q3 2025.
- Quarterly Non-cash Items rose 57.67% year-over-year to -$20.8 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$99.1 million (up 55.8% YoY) and the FY2022 annual result came in at -$402.5 million, down 11.37% from the prior year.
- Non-cash Items fell to -$20.8 million in Q3 2025, from $3.5 million in the prior quarter.
- In the past five years, Non-cash Items ranged from a high of $3.5 million in Q2 2025 to a low of -$402.5 million in Q4 2022.
- A 5-year average of -$103.2 million and a median of -$77.3 million in 2021 frame the typical range for Non-cash Items.
- Annual changes were most pronounced in 2023 — Non-cash Items slumped 72.52% — and 2025, when it soared 137.88%.
- Tracing LEGN's Non-cash Items over 5 years: stood at -$361.4 million in 2021, then retreated by 11.37% to -$402.5 million in 2022, then soared by 81.58% to -$74.2 million in 2023, then jumped by 33.73% to -$49.1 million in 2024, then jumped by 57.67% to -$20.8 million in 2025.
- The last three Non-cash Items figures came in at -$20.8 million (Q3 2025), $3.5 million (Q2 2025), and -$32.7 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -20.81 Mn |
| Sep 30, 2025 | -20.81 Mn |
| Jun 30, 2025 | 3.52 Mn |
| Jun 30, 2025 | 3.52 Mn |
| Mar 31, 2025 | -32.70 Mn |
| Mar 31, 2025 | -32.70 Mn |
| Sep 30, 2024 | -49.15 Mn |
| Sep 30, 2024 | -49.15 Mn |
| Jun 30, 2024 | -9.30 Mn |
| Jun 30, 2024 | -9.30 Mn |
| Mar 31, 2024 | -91.66 Mn |
| Mar 31, 2024 | -91.66 Mn |
| Sep 30, 2023 | -74.16 Mn |
| Sep 30, 2023 | -74.16 Mn |
| Jun 30, 2023 | -83.15 Mn |
| Jun 30, 2023 | -83.15 Mn |
| Mar 31, 2023 | -111.12 Mn |
| Mar 31, 2023 | -111.12 Mn |
| Dec 31, 2022 | -402.54 Mn |
| Dec 31, 2022 | -402.54 Mn |